PEG-Intron
Phase 2Small molecule
Merck & Co.PEG-Intron is one of 151 small molecule programs targeting Lymphoma. It is currently in Phase 2.
5
Indications
11
Total Trials
0
Active Trials
150
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1PEG-Intron
Merck & Co.Phase 2
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Melanoma2 trials
Chronic Hepatitis2 trials
Treatment1 trial
4 more indications
Colchicine1 trial
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
Completed·—·Phase 4·NCT00179413·549 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEG-Intron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company